16
Participants
Start Date
May 31, 2011
Primary Completion Date
November 30, 2014
Study Completion Date
November 30, 2014
Optimal muscle activation therapy
The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
Standard Therapy
Sunnybrook Health Sciences Centre, Toronto
Collaborators (1)
Allergan
INDUSTRY
Sunnybrook Health Sciences Centre
OTHER